Analysts Set $23.00 Price Target for Recro Pharma Inc. (REPH)
Shares of Recro Pharma Inc. (NASDAQ:REPH) have been given a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy rating.
Analysts have set a twelve-month consensus price objective of $23.00 for the company and are expecting that the company will post ($0.71) earnings per share for the current quarter, according to Zacks. Zacks has also given Recro Pharma an industry rank of 113 out of 265 based on the ratings given to its competitors.
A number of research firms have recently weighed in on REPH. Brean Capital initiated coverage on Recro Pharma in a research report on Monday, October 3rd. They issued a “buy” rating and a $21.00 price objective for the company. Zacks Investment Research upgraded Recro Pharma from a “sell” rating to a “hold” rating in a research note on Friday, August 26th. Janney Montgomery Scott initiated coverage on Recro Pharma in a research note on Monday, August 29th. They issued a “buy” rating and a $21.00 target price for the company. HC Wainwright restated a “buy” rating on shares of Recro Pharma in a research note on Monday, July 18th. Finally, Roth Capital initiated coverage on Recro Pharma in a research note on Friday, September 16th. They issued a “buy” rating and a $24.00 target price for the company.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/analysts-set-23-00-price-target-for-recro-pharma-inc-reph.html
In related news, major shareholder Healthcare Master Fun Broadfin acquired 390,000 shares of Recro Pharma stock in a transaction on Tuesday, August 16th. The stock was acquired at an average price of $7.50 per share, for a total transaction of $2,925,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 39.30% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Fund Advisors raised its position in shares of Recro Pharma by 37.5% in the second quarter. BlackRock Fund Advisors now owns 15,268 shares of the specialty pharmaceutical company’s stock valued at $121,000 after buying an additional 4,163 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Recro Pharma by 30.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 49,947 shares of the specialty pharmaceutical company’s stock valued at $397,000 after buying an additional 11,682 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Recro Pharma by 0.4% in the second quarter. Vanguard Group Inc. now owns 107,252 shares of the specialty pharmaceutical company’s stock valued at $852,000 after buying an additional 400 shares in the last quarter. Finally, Stonepine Capital Management LLC raised its position in shares of Recro Pharma by 81.0% in the second quarter. Stonepine Capital Management LLC now owns 428,670 shares of the specialty pharmaceutical company’s stock valued at $3,408,000 after buying an additional 191,796 shares in the last quarter. Institutional investors and hedge funds own 36.38% of the company’s stock.
Recro Pharma (NASDAQ:REPH) traded up 0.51% during trading on Monday, hitting $7.90. The stock had a trading volume of 15,998 shares. Recro Pharma has a 52-week low of $5.59 and a 52-week high of $12.50. The company’s market cap is $77.97 million. The firm’s 50-day moving average price is $9.05 and its 200-day moving average price is $8.16.
Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings data on Thursday, August 11th. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.78) by $0.05. The business earned $17.30 million during the quarter, compared to analyst estimates of $18.70 million. Recro Pharma had a negative return on equity of 52.80% and a negative net margin of 8.70%. Analysts predict that Recro Pharma will post ($3.13) EPS for the current fiscal year.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.